Actionable targets in patients with cisplatin-resistant advanced germ cell tumours
1 Views
administrator
06/29/23
Dr Bagrodia talks to ecancertv at ASCO GU 2016 about actionable targets in patients with cisplatin-resistant advanced germ cell tumours.
Approximately 30% of patients with advanced germ cell tumour will progress after first-line chemotherapy.
Nearly half of these patients will die of progressive germ cell tumours.
Dr Bragrodia describes actionable alterations that may guide treatment selection in a significant proportion of patients with cisplatin-resistant advanced germ cell tumours.
Targeted sequencing of these patients may allow enriched clinical trials in the future with patients whose tumours harbour alterations in the drug target of interest.
-
Category
Show more
Facebook Comments
No comments found